Oncological Emergencies:@0.672868:0.035749:0.914547:0.035749:0.914547:0.019993:0.672868:0.019993:0.016722:0.011738:0.012450:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.005330:0.010314:0.018049:0.012508:0.005805:0.012950:0.012508:0.011738:0.012450:0.003848:0.012508:0.007466
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
117:@0.950254:0.038184:0.981863:0.038184:0.981863:0.018587:0.950254:0.018587:0.010536:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
the  treatment  of  spinal  cord  compression :@0.120589:0.094740:0.479902:0.094740:0.479902:0.080735:0.120589:0.080735:0.005456:0.010092:0.010776:0.004738:0.004986:0.005456:0.004736:0.010776:0.011340:0.005456:0.015702:0.010776:0.010092:0.005456:0.004738:0.004986:0.010861:0.005029:0.004738:0.004986:0.006294:0.011323:0.003079:0.010092:0.011340:0.003079:0.004738:0.004986:0.010724:0.010861:0.004702:0.011374:0.004738:0.004986:0.010724:0.010861:0.015702:0.011323:0.004736:0.010776:0.006294:0.006294:0.003079:0.010861:0.010432:0.004738
caused by metastatic cancer: a randomised :@0.120589:0.108874:0.479868:0.108874:0.479868:0.094869:0.120589:0.094869:0.010724:0.011340:0.010057:0.006294:0.010776:0.011374:0.003592:0.011323:0.008826:0.003592:0.015702:0.010776:0.005456:0.011340:0.006294:0.005456:0.011340:0.005456:0.003079:0.010724:0.003592:0.010724:0.011340:0.010092:0.010724:0.010776:0.004806:0.004396:0.003592:0.011340:0.003592:0.004806:0.011340:0.010092:0.011374:0.010861:0.015702:0.003079:0.006294:0.010776:0.011718:0.004738
trial. :@0.120589:0.123009:0.157483:0.123009:0.157483:0.109004:0.120589:0.109004:0.005456:0.004806:0.003079:0.011340:0.003079:0.004396:0.004738
Lancet:@0.157141:0.123009:0.213432:0.123009:0.213432:0.109004:0.157141:0.109004:0.007560:0.011340:0.010092:0.010724:0.010776:0.005798
. 2005;336(9486);643-648.:@0.213090:0.123009:0.407960:0.123009:0.407960:0.109004:0.213090:0.109004:0.004396:0.004396:0.009134:0.009134:0.009134:0.009134:0.004396:0.009134:0.009134:0.009134:0.005969:0.009134:0.009134:0.009134:0.009134:0.005969:0.004396:0.009134:0.009134:0.009134:0.005337:0.009134:0.009134:0.009134:0.004738
7.:@0.084242:0.137144:0.098456:0.137144:0.098456:0.123138:0.084242:0.123138:0.009476:0.004738
  Klastersky J, de Naurois J, Rolston K, :@0.120589:0.137144:0.429203:0.137144:0.429203:0.123138:0.120589:0.123138:0.004738:-0.004738:0.010109:0.003421:0.011682:0.006636:0.005798:0.011118:0.005148:0.006636:0.008586:0.009168:0.006961:0.008244:0.004738:0.006961:0.011716:0.011118:0.006961:0.012657:0.011682:0.010399:0.005080:0.011203:0.003421:0.006636:0.006961:0.008244:0.004738:0.006961:0.010382:0.011203:0.003421:0.006636:0.005798:0.011203:0.010434:0.006961:0.010109:0.004738:0.004738
et al.:@0.431427:0.137144:0.475145:0.137144:0.475145:0.123138:0.431427:0.123138:0.011118:0.005798:0.006961:0.011682:0.003421:0.004738
Management  of febrile neutropaenia::@0.120589:0.151278:0.475157:0.151278:0.475157:0.137273:0.120589:0.137273:0.015719:0.011682:0.010434:0.011682:0.011511:0.011118:0.016044:0.011118:0.010434:0.005798:0.004738:0.012731:0.011203:0.005371:0.017481:0.005371:0.011118:0.011665:0.005148:0.003421:0.003421:0.011118:0.017481:0.010434:0.011118:0.010399:0.005798:0.005070:0.011203:0.011665:0.011682:0.011118:0.010434:0.003421:0.011682:0.004738
ESMO Clinical  Practice Guidelines. :@0.120589:0.165413:0.417257:0.165413:0.417257:0.151408:0.120589:0.151408:0.009168:0.008518:0.015719:0.014864:0.007372:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.004738:0.002644:0.010126:0.005148:0.011682:0.011067:0.005798:0.003421:0.011067:0.011118:0.007372:0.014915:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.006636:0.004738:0.004738
Annals:@0.419892:0.165413:0.475156:0.165413:0.475156:0.151408:0.419892:0.151408:0.012657:0.010434:0.010434:0.011682:0.003421:0.006636
of Oncology. :@0.120589:0.179548:0.234248:0.179548:0.234248:0.165542:0.120589:0.165542:0.011203:0.005371:0.004738:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.004738
2016 27(Suppl5):v111-v118.:@0.234231:0.179548:0.454569:0.179548:0.454569:0.165542:0.234231:0.165542:0.009476:0.009476:0.009476:0.009476:0.004755:0.009476:0.009476:0.006312:0.008518:0.010399:0.011665:0.011665:0.003421:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
;:@0.272151:0.179548:0.276889:0.179548:0.276889:0.165542:0.272151:0.165542:0.004738
8.:@0.084242:0.193682:0.098456:0.193682:0.098456:0.179677:0.084242:0.179677:0.009476:0.004738
  National Comprehensive Cancer Network:@0.120589:0.193682:0.475164:0.193682:0.475164:0.179677:0.120589:0.179677:0.004738:-0.004738:0.012657:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.006842:0.013906:0.011203:0.016044:0.011665:0.005077:0.011118:0.010434:0.011118:0.010434:0.006636:0.003421:0.009476:0.011118:0.006859:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.006847:0.012657:0.011118:0.005798:0.014214:0.011203:0.005148:0.008586
(NCCN): Clinical Practice Guidelines in On-:@0.120589:0.207817:0.475142:0.207817:0.475142:0.193812:0.120589:0.193812:0.006312:0.012657:0.013906:0.013906:0.012657:0.006312:0.004738:0.004481:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.004498:0.010126:0.005148:0.011682:0.011067:0.005798:0.003421:0.011067:0.011118:0.004480:0.014915:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.006636:0.004490:0.003421:0.010434:0.004488:0.014864:0.010434:0.005679
cology. Prevention and Treatment of Can-:@0.120589:0.221951:0.475169:0.221951:0.475169:0.207946:0.120589:0.207946:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.005617:0.010126:0.005077:0.011118:0.009476:0.011118:0.010434:0.005798:0.003421:0.011203:0.010434:0.005627:0.011682:0.010434:0.011716:0.005627:0.006773:0.005077:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.005617:0.011203:0.005371:0.005627:0.013906:0.011682:0.010434:0.005679
cer-Related Infections. :@0.120589:0.236086:0.312740:0.236086:0.312740:0.222081:0.120589:0.222081:0.011067:0.011118:0.005148:0.005679:0.010382:0.011118:0.003421:0.011682:0.005798:0.011118:0.011716:0.005080:0.003866:0.010434:0.005371:0.011118:0.011067:0.005798:0.003421:0.011203:0.010434:0.006636:0.004738:0.004738
J Natl Compr Canc:@0.313082:0.236086:0.475180:0.236086:0.475180:0.222081:0.313082:0.222081:0.008244:0.005080:0.012657:0.011682:0.005798:0.003421:0.005080:0.013906:0.011203:0.016044:0.011665:0.005148:0.005080:0.013906:0.011682:0.010434:0.011067
Netw:@0.120589:0.250221:0.164376:0.250221:0.164376:0.236215:0.120589:0.236215:0.012657:0.011118:0.005798:0.014214
. 2016 Jul;14(7):882-913.:@0.164376:0.250221:0.356356:0.250221:0.356356:0.236215:0.164376:0.236215:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.008244:0.010399:0.003421:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
9.:@0.084242:0.264355:0.098456:0.264355:0.098456:0.250350:0.084242:0.250350:0.009476:0.004738
  Flowers CR, Seidenfeld J, Bow EJ, :@0.120589:0.264355:0.422994:0.264355:0.422994:0.250350:0.120589:0.250350:0.004738:-0.004738:0.008296:0.003421:0.011203:0.014214:0.011118:0.005148:0.006636:0.010057:0.013906:0.010382:0.004738:0.010057:0.008518:0.011118:0.003421:0.011716:0.011118:0.010434:0.005371:0.011118:0.003421:0.011716:0.010057:0.008244:0.004738:0.010057:0.009818:0.011203:0.014214:0.010057:0.009168:0.008244:0.004738:0.672143
et al:@0.428314:0.264355:0.470390:0.264355:0.470390:0.250350:0.428314:0.250350:0.011118:0.005798:0.010057:0.011682:0.003421
.:@0.470390:0.264355:0.475128:0.264355:0.475128:0.250350:0.470390:0.250350:0.004738
American Society of Clinical  Oncology:@0.120589:0.278490:0.475161:0.278490:0.475161:0.264485:0.120589:0.264485:0.012657:0.016044:0.011118:0.005148:0.003421:0.011067:0.011682:0.010434:0.013119:0.008518:0.011203:0.011067:0.003421:0.011118:0.005798:0.009168:0.013119:0.011203:0.005371:0.013119:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.004738:0.008397:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168
(ASCO): Antimicrobial prophylaxis and out-:@0.120589:0.292625:0.475145:0.292625:0.475145:0.278619:0.120589:0.278619:0.006312:0.012657:0.008518:0.013906:0.014864:0.006312:0.004738:0.004618:0.012657:0.010434:0.005798:0.003421:0.016044:0.003421:0.011067:0.005073:0.011203:0.011665:0.003421:0.011682:0.003421:0.004618:0.011665:0.005080:0.011203:0.011665:0.010434:0.009168:0.003421:0.011682:0.008210:0.003421:0.006636:0.004610:0.011682:0.010434:0.011716:0.004618:0.011203:0.010399:0.005780:0.005679
patient management of fever and neutro-:@0.120589:0.306759:0.475157:0.306759:0.475157:0.292754:0.120589:0.292754:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.005292:0.016044:0.011682:0.010434:0.011682:0.011511:0.011118:0.016044:0.011118:0.010434:0.005798:0.005285:0.011203:0.005371:0.005289:0.005371:0.011118:0.009476:0.011118:0.005148:0.005289:0.011682:0.010434:0.011716:0.005294:0.010434:0.011118:0.010399:0.005798:0.005070:0.011203:0.005679
paenia in adults treated for malignancy. :@0.120589:0.320894:0.465789:0.320894:0.465789:0.306889:0.120589:0.306889:0.011665:0.011682:0.011118:0.010434:0.003421:0.011682:0.005867:0.003421:0.010434:0.005867:0.011682:0.011716:0.010399:0.003421:0.005798:0.006636:0.005867:0.005798:0.005077:0.011118:0.011682:0.005798:0.011118:0.011716:0.005867:0.005371:0.011203:0.005148:0.005853:0.016044:0.011682:0.003421:0.003421:0.011511:0.010434:0.011682:0.010434:0.011067:0.009168:0.004738:0.004738
J:@0.466901:0.320894:0.475145:0.320894:0.475145:0.306889:0.466901:0.306889:0.008244
Clin Oncol. :@0.120589:0.335028:0.216972:0.335028:0.216972:0.321023:0.120589:0.321023:0.013906:0.003421:0.003421:0.010434:0.004738:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738:0.004738
2013 Feb 20;31(6):794-810.:@0.216972:0.335028:0.432179:0.335028:0.432179:0.321023:0.216972:0.321023:0.009476:0.009476:0.009476:0.009476:0.004738:0.008296:0.011118:0.011665:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
10.   National Comprehensive Cancer Network:@0.084242:0.349163:0.475164:0.349163:0.475164:0.335158:0.084242:0.335158:0.009476:0.009476:0.004738:0.012657:0.004738:-0.004738:0.012657:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.006842:0.013906:0.011203:0.016044:0.011665:0.005077:0.011118:0.010434:0.011118:0.010434:0.006636:0.003421:0.009476:0.011118:0.006859:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.006847:0.012657:0.011118:0.005798:0.014214:0.011203:0.005148:0.500464
(NCCN): Clinical Practice Guidelines in On-:@0.120589:0.363298:0.475142:0.363298:0.475142:0.349292:0.120589:0.349292:0.006312:0.012657:0.013906:0.013906:0.012657:0.006312:0.004738:0.004481:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.004498:0.010126:0.005148:0.011682:0.011067:0.005798:0.003421:0.011067:0.011118:0.004480:0.014915:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.006636:0.004490:0.003421:0.010434:0.004488:0.014864:0.010434:0.005679
cology.  Myeloid Growth  Factors. Version:@0.120589:0.377432:0.475161:0.377432:0.475161:0.363427:0.120589:0.363427:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.004738:0.005769:0.015719:0.009168:0.011118:0.003421:0.011203:0.003421:0.011716:0.010519:0.014915:0.005080:0.011203:0.014214:0.005798:0.010434:0.004738:0.005768:0.008296:0.011682:0.011067:0.005798:0.011203:0.005138:0.006636:0.004738:0.010519:0.010280:0.011118:0.005148:0.006636:0.003421:0.011203:0.010434
2.2017;MGF-A 1-4.:@0.120589:0.391567:0.268816:0.391567:0.268816:0.377562:0.120589:0.377562:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.015719:0.014915:0.008296:0.005679:0.012657:0.004738:0.009476:0.005679:0.009476:0.004738
11.  Aapro MS, Bohlius J, Cameron DA, :@0.084242:0.405702:0.426395:0.405702:0.426395:0.391696:0.084242:0.391696:0.009476:0.009476:0.004738:0.012657:0.000000:0.012657:0.011682:0.011665:0.005080:0.011203:0.008381:0.015719:0.008518:0.004738:0.008381:0.009818:0.011203:0.010434:0.003421:0.003421:0.010399:0.006636:0.008381:0.008244:0.004738:0.008381:0.013906:0.011682:0.016044:0.011118:0.005077:0.011203:0.010434:0.008381:0.012726:0.012657:0.004738:0.463148
et al.:@0.430038:0.405702:0.475176:0.405702:0.475176:0.391696:0.430038:0.391696:0.011118:0.005798:0.008381:0.011682:0.003421:0.004738
2010 update  of  EORTC  guidelines for  the:@0.120589:0.419836:0.475152:0.419836:0.475152:0.405831:0.120589:0.405831:0.009476:0.009476:0.009476:0.009476:0.008296:0.010399:0.011665:0.011716:0.011682:0.005798:0.011118:0.004738:0.003549:0.011203:0.005371:0.004738:0.003546:0.009168:0.014864:0.010487:0.007286:0.013906:0.004738:0.003547:0.011511:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.006636:0.008296:0.005371:0.011203:0.005148:0.004738:0.003542:0.005798:0.010434:0.011118
use of granulocyte-colony-stimulating fac-:@0.120589:0.433971:0.475154:0.433971:0.475154:0.419966:0.120589:0.419966:0.010399:0.006636:0.011118:0.006226:0.011203:0.005371:0.006226:0.011511:0.005148:0.011682:0.010434:0.010399:0.003421:0.011203:0.011067:0.009168:0.005798:0.011118:0.005679:0.011067:0.011203:0.003421:0.011203:0.010434:0.009168:0.005679:0.006636:0.005798:0.003421:0.016044:0.010399:0.003421:0.011682:0.005798:0.003421:0.010434:0.011511:0.006217:0.005371:0.011682:0.011067:0.005679
tor to reduce the incidence of chemother-:@0.120589:0.448106:0.475145:0.448106:0.475145:0.434100:0.120589:0.434100:0.005798:0.011203:0.005148:0.004858:0.005798:0.011203:0.004861:0.005078:0.011118:0.011716:0.010399:0.011067:0.011118:0.004863:0.005798:0.010434:0.011118:0.004875:0.003421:0.010434:0.011067:0.003421:0.011716:0.011118:0.010434:0.011067:0.011118:0.004866:0.011203:0.005371:0.004863:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005111:0.005679
apy-induced febrile neutropaenia in adult:@0.120589:0.462240:0.475171:0.462240:0.475171:0.448235:0.120589:0.448235:0.011682:0.011665:0.009168:0.005679:0.003421:0.010434:0.011716:0.010399:0.011067:0.011118:0.011716:0.006089:0.005371:0.011118:0.011665:0.005148:0.003421:0.003421:0.011118:0.006089:0.010434:0.011118:0.010399:0.005798:0.005071:0.011203:0.011665:0.011682:0.011118:0.010434:0.003421:0.011682:0.006089:0.003421:0.010434:0.006089:0.011682:0.011716:0.010399:0.003421:0.005798
patients with lymphoproliferative disorders:@0.120589:0.476375:0.475168:0.476375:0.475168:0.462369:0.120589:0.462369:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.007218:0.014214:0.003421:0.005798:0.010434:0.007218:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.011665:0.005082:0.011203:0.003421:0.003421:0.005371:0.011118:0.005148:0.011682:0.005798:0.003421:0.009476:0.011118:0.007218:0.011716:0.003421:0.006636:0.011203:0.005049:0.011716:0.011118:0.005148:0.006636
and solid tumours. :@0.120589:0.490509:0.288357:0.490509:0.288357:0.476504:0.120589:0.476504:0.011682:0.010434:0.011716:0.011220:0.006636:0.011203:0.003421:0.003421:0.011716:0.011220:0.005798:0.010399:0.016044:0.011203:0.010391:0.005148:0.006636:0.004738:0.004738
European  Journal  of:@0.294814:0.490509:0.475149:0.490509:0.475149:0.476504:0.294814:0.476504:0.009168:0.010399:0.005148:0.011203:0.011665:0.011118:0.011682:0.010434:0.004738:0.006467:0.008244:0.011203:0.010399:0.005148:0.010434:0.011682:0.003421:0.004738:0.006467:0.011203:0.005371
Cancer. :@0.120589:0.504644:0.193420:0.504644:0.193420:0.490639:0.120589:0.490639:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004738
2011;47:8-32.:@0.193402:0.504644:0.298577:0.504644:0.298577:0.490639:0.193402:0.490639:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.005679:0.009476:0.009476:0.004738
12.  National Institute for  Health and Care Ex-:@0.084242:0.518779:0.475163:0.518779:0.475163:0.504773:0.084242:0.504773:0.009476:0.009476:0.004738:0.012657:0.000000:0.012657:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.007748:0.003866:0.010434:0.006636:0.005798:0.003421:0.005798:0.010399:0.005798:0.011118:0.007748:0.005371:0.011203:0.005148:0.004738:0.002993:0.011682:0.011118:0.011682:0.003421:0.005798:0.010434:0.007748:0.011682:0.010434:0.011716:0.007748:0.013906:0.011682:0.005080:0.011118:0.007748:0.009168:0.008210:0.250845
cellence (NICE). Neutropaenic sepsis::@0.120589:0.532913:0.475133:0.532913:0.475133:0.518908:0.120589:0.518908:0.011067:0.011118:0.003421:0.003421:0.011118:0.010434:0.011067:0.011118:0.019448:0.006312:0.012657:0.003866:0.013906:0.009168:0.006312:0.004738:0.019448:0.012657:0.011118:0.010399:0.005798:0.005068:0.011203:0.011665:0.011682:0.011118:0.010434:0.003421:0.011067:0.019448:0.006636:0.011118:0.011665:0.006636:0.003421:0.006636:0.004738
prevention  and management  in people:@0.120589:0.547048:0.475164:0.547048:0.475164:0.533043:0.120589:0.533043:0.011665:0.005080:0.011118:0.009476:0.011118:0.010434:0.005798:0.003421:0.011203:0.010434:0.004738:0.005526:0.011682:0.010434:0.011716:0.010280:0.016044:0.011682:0.010434:0.011682:0.011511:0.011118:0.016044:0.011118:0.010434:0.005798:0.004738:0.005525:0.003421:0.010434:0.010280:0.011665:0.011118:0.011203:0.011665:0.003421:0.011118
with cancer. Clinical Guideline (CG151).:@0.120589:0.561183:0.475118:0.561183:0.475118:0.547177:0.120589:0.547177:0.014214:0.003421:0.005798:0.010434:0.010331:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.010331:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.010331:0.014915:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.010331:0.006312:0.013906:0.014915:0.009476:0.009476:0.009476:0.006312:0.004738
Published 19 September 2012. Nice.org.uk/:@0.120589:0.575317:0.475147:0.575317:0.475147:0.561312:0.120589:0.561312:0.010126:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004943:0.009476:0.009476:0.004943:0.008518:0.011118:0.011665:0.005798:0.011118:0.016044:0.011665:0.011118:0.005148:0.004935:0.009476:0.009476:0.009476:0.009476:0.004738:0.004953:0.012657:0.003421:0.011067:0.011118:0.004738:0.011203:0.005148:0.011511:0.004738:0.010399:0.008586:0.007475
guidance/cg151. Accessed January 2018.:@0.120589:0.589452:0.470784:0.589452:0.470784:0.575447:0.120589:0.575447:0.011511:0.010399:0.003421:0.011716:0.011682:0.010434:0.011067:0.011118:0.007475:0.011067:0.011511:0.009476:0.009476:0.009476:0.004738:0.004738:0.012657:0.011067:0.011067:0.011118:0.006636:0.006636:0.011118:0.011716:0.004738:0.008244:0.011682:0.010434:0.010399:0.011682:0.005148:0.009168:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
13.   Klastersky J,  Paesmans M,  Rubenstein  EB,:@0.084242:0.603586:0.475145:0.603586:0.475145:0.589581:0.084242:0.589581:0.009476:0.009476:0.004738:0.012657:0.004738:-0.004738:0.010109:0.003421:0.011682:0.006636:0.005798:0.011118:0.005148:0.006636:0.008586:0.009168:0.008672:0.008244:0.004738:0.004738:0.003917:0.010126:0.011682:0.011118:0.006636:0.016044:0.011682:0.010434:0.006636:0.008672:0.015719:0.004738:0.004738:0.003925:0.010382:0.010399:0.011665:0.011118:0.010434:0.006636:0.005798:0.011118:0.003421:0.010434:0.004738:0.003925:0.009168:0.009818:0.126565
et al.:@0.120589:0.617721:0.162343:0.617721:0.162343:0.603716:0.120589:0.603716:0.011118:0.005798:0.004996:0.011682:0.003421:0.004738
 The Multinational Association for Sup-:@0.162343:0.617721:0.475147:0.617721:0.475147:0.603716:0.162343:0.603716:0.005001:0.007286:0.010434:0.011118:0.004993:0.015719:0.010399:0.003421:0.005798:0.003421:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.005003:0.012657:0.006636:0.006636:0.011203:0.011067:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.005000:0.005371:0.011203:0.005148:0.004993:0.008518:0.010399:0.011665:0.005679
portive  Care  in  Cancer  Risk Index:  a  mul-:@0.120589:0.631856:0.475154:0.631856:0.475154:0.617850:0.120589:0.617850:0.011665:0.011203:0.005148:0.005798:0.003421:0.009476:0.011118:0.004738:0.002603:0.013906:0.011682:0.005080:0.011118:0.004738:0.002605:0.003421:0.010434:0.004738:0.002607:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.002600:0.010382:0.003421:0.006636:0.008586:0.007355:0.003866:0.010434:0.011716:0.011118:0.008210:0.004738:0.004738:0.002602:0.011682:0.004738:0.002608:0.016044:0.010399:0.003421:0.005679
tinational scoring system for  identifying:@0.120589:0.645990:0.475166:0.645990:0.475166:0.631985:0.120589:0.631985:0.005798:0.003421:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.013735:0.006636:0.011067:0.011203:0.005148:0.003421:0.010434:0.011511:0.013735:0.006636:0.009168:0.006636:0.005798:0.011118:0.016044:0.013735:0.005371:0.011203:0.005148:0.004738:0.008983:0.003421:0.011716:0.011118:0.010434:0.005798:0.003421:0.005371:0.009168:0.003421:0.010434:0.011511
low-risk febrile neutropenic cancer pa-:@0.559983:0.094904:0.914531:0.094904:0.914531:0.080899:0.559983:0.080899:0.003421:0.011203:0.014214:0.005679:0.005148:0.003421:0.006636:0.008586:0.013427:0.005371:0.011118:0.011665:0.005148:0.003421:0.003421:0.011118:0.013427:0.010434:0.011118:0.010399:0.005798:0.005071:0.011203:0.011665:0.011118:0.010434:0.003421:0.011067:0.013427:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.013427:0.011665:0.011682:0.005679
tients. :@0.559983:0.109404:0.612664:0.109404:0.612664:0.095398:0.559983:0.095398:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004738:0.004738
J Clin Oncol:@0.612664:0.109404:0.712554:0.109404:0.712554:0.095398:0.612664:0.095398:0.008244:0.004738:0.013906:0.003421:0.003421:0.010434:0.004738:0.014864:0.010434:0.011067:0.011203:0.003421
. 2000;18:3038-3051.:@0.712554:0.109404:0.874584:0.109404:0.874584:0.095398:0.712554:0.095398:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
14.  Lafferty FW. Differential diagnosis of hyper-:@0.523636:0.123903:0.914558:0.123903:0.914558:0.109897:0.523636:0.109897:0.009476:0.009476:0.004738:0.012657:0.000000:0.007902:0.011682:0.005422:0.005371:0.011118:0.005148:0.005798:0.009168:0.005858:0.008296:0.015148:0.004738:0.005867:0.012726:0.003421:0.005426:0.005371:0.011118:0.005077:0.011118:0.010434:0.005798:0.003421:0.011682:0.003421:0.005867:0.011716:0.003421:0.011682:0.011511:0.010434:0.011203:0.006636:0.003421:0.006636:0.005867:0.011203:0.005371:0.005867:0.010434:0.009168:0.011665:0.011118:0.005148:0.005679
calcaemia. :@0.559983:0.138402:0.660642:0.138402:0.660642:0.124397:0.559983:0.124397:0.011067:0.011682:0.003421:0.011067:0.011682:0.011118:0.016044:0.003421:0.011682:0.004738:0.004738
Journal of  Bone Mineral  Re-:@0.666081:0.138402:0.914560:0.138402:0.914560:0.124397:0.666081:0.124397:0.008244:0.011203:0.010399:0.005138:0.010434:0.011682:0.003421:0.010177:0.011203:0.005371:0.004738:0.005427:0.009818:0.011203:0.010434:0.011118:0.010177:0.015719:0.003421:0.010434:0.011118:0.005148:0.011682:0.003421:0.004738:0.005431:0.010382:0.011118:0.005679
search:@0.559983:0.152901:0.616068:0.152901:0.616068:0.138896:0.559983:0.138896:0.006636:0.011118:0.011682:0.005148:0.011067:0.010434
. 1991;6(Suppl 2):S51.:@0.616068:0.152901:0.787112:0.152901:0.787112:0.138896:0.616068:0.138896:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.006312:0.008518:0.010399:0.011665:0.011665:0.003421:0.004738:0.009476:0.006312:0.004738:0.008518:0.009476:0.009476:0.004738
15.  UpToDate © Consensus-based Guide-:@0.523636:0.167400:0.914539:0.167400:0.914539:0.153395:0.523636:0.153395:0.009479:0.009479:0.004738:0.012650:0.000000:0.011888:0.012349:0.007133:0.011888:0.013410:0.012366:0.006483:0.011802:0.012315:0.013461:0.012315:0.014590:0.011888:0.011118:0.007321:0.011802:0.011118:0.007321:0.011084:0.007321:0.006363:0.012349:0.012366:0.007321:0.011802:0.012401:0.012315:0.015599:0.011084:0.004105:0.012401:0.011802:0.322564
lines. Malignancy-related superior vena:@0.559983:0.181899:0.914538:0.181899:0.914538:0.167894:0.559983:0.167894:0.004105:0.004105:0.011118:0.011802:0.007321:0.005422:0.006414:0.016403:0.012366:0.004105:0.004105:0.012195:0.011118:0.012366:0.011118:0.011751:0.009852:0.006363:0.005762:0.011802:0.004105:0.012366:0.006483:0.011802:0.012401:0.006414:0.007321:0.011084:0.012349:0.011802:0.005833:0.004105:0.011888:0.005833:0.006414:0.010160:0.011802:0.011118:0.011682
cava syndrome.  https://www.upto-:@0.559983:0.196399:0.914555:0.196399:0.914555:0.182393:0.559983:0.182393:0.012948:0.013564:0.011357:0.013564:0.008911:0.008518:0.011049:0.012315:0.013598:0.006960:0.013085:0.017925:0.012999:0.006619:0.004738:0.004173:0.012315:0.007680:0.007680:0.013547:0.008518:0.006619:0.009356:0.009356:0.016095:0.016095:0.016095:0.006619:0.012281:0.013547:0.007680:0.013085:0.005679
date.com/contents/malignancy-relat- :@0.559983:0.210898:0.918405:0.210898:0.918405:0.196892:0.559983:0.196892:0.012401:0.012366:0.006483:0.011802:0.005422:0.011751:0.011888:0.016728:0.008159:0.011751:0.012401:0.011631:0.006996:0.012315:0.011631:0.006996:0.007834:0.008672:0.017241:0.012880:0.004618:0.004618:0.012709:0.011631:0.012880:0.011631:0.012264:0.010365:0.006876:0.006276:0.012315:0.004618:0.012880:0.006996:0.005663:0.004738
ed-superior-vena-cava-syndrome?search:@0.559983:0.225397:0.910516:0.225397:0.910516:0.211392:0.559983:0.211392:0.011289:0.011888:0.005850:0.006808:0.010570:0.011836:0.011289:0.005319:0.003592:0.011374:0.005319:0.005850:0.009647:0.011289:0.010605:0.011853:0.005850:0.011238:0.011853:0.009647:0.011853:0.005850:0.006808:0.009339:0.010605:0.011888:0.005249:0.011374:0.016215:0.011289:0.010280:0.006808:0.011289:0.011853:0.005198:0.011238:0.010434
=superior%20vena%20cava%20syndro:@0.559983:0.239896:0.914298:0.239896:0.914298:0.225891:0.559983:0.225891:0.011049:0.008005:0.011768:0.013034:0.012486:0.006517:0.004789:0.012572:0.006517:0.014624:0.010844:0.010844:0.010844:0.012486:0.011802:0.013051:0.014624:0.010844:0.010844:0.012435:0.013051:0.010844:0.013051:0.014624:0.010844:0.010844:0.008005:0.010536:0.011802:0.013085:0.006447:0.011203
me&source=search_result&selectedTitl:@0.559983:0.254395:0.908200:0.254395:0.908200:0.240390:0.559983:0.240390:0.016899:0.011973:0.013803:0.007492:0.012059:0.011255:0.005882:0.011922:0.011973:0.011220:0.007492:0.011973:0.012537:0.005884:0.011922:0.011289:0.009407:0.005934:0.011973:0.007492:0.011255:0.004276:0.006654:0.013803:0.007492:0.011973:0.004276:0.011973:0.011922:0.006654:0.011973:0.012572:0.008665:0.004276:0.006654:0.003421
e=1~150&usage_type=default&display_:@0.559983:0.268894:0.912675:0.268894:0.912675:0.254889:0.559983:0.254889:0.011802:0.011049:0.010160:0.011049:0.010160:0.010160:0.010160:0.013632:0.011084:0.007321:0.012366:0.012195:0.011802:0.009236:0.006483:0.009852:0.012349:0.011802:0.011049:0.012401:0.011802:0.006055:0.012366:0.011084:0.004105:0.006483:0.013632:0.012401:0.004105:0.007321:0.012349:0.004105:0.012366:0.009852:0.008552
rank=1. Accessed January 2018.:@0.559983:0.283394:0.845882:0.283394:0.845882:0.269388:0.559983:0.269388:0.005833:0.012366:0.011118:0.009271:0.011049:0.010160:0.005422:0.005422:0.013341:0.011751:0.011751:0.011802:0.007321:0.007321:0.011802:0.012401:0.005422:0.008928:0.012366:0.011118:0.011084:0.012366:0.005833:0.009852:0.005422:0.010160:0.010160:0.010160:0.010160:0.004738
16.   Schraufnagel  DE, Hill R,  Leech JA, :@0.523636:0.297893:0.863662:0.297893:0.863662:0.283887:0.523636:0.283887:0.009476:0.009476:0.004738:0.012657:0.004738:-0.004738:0.008518:0.011067:0.010434:0.005148:0.011682:0.010399:0.005371:0.010434:0.011682:0.011511:0.011118:0.003421:0.004738:0.004687:0.012726:0.009168:0.004738:0.009442:0.011682:0.003421:0.003421:0.003421:0.009442:0.010382:0.004738:0.004738:0.004695:0.007902:0.011118:0.011118:0.011067:0.010434:0.009442:0.008244:0.012657:0.004738:0.182693
et  al:@0.868358:0.297893:0.909810:0.297893:0.909810:0.283887:0.868358:0.283887:0.011118:0.005798:0.004738:0.004695:0.011682:0.003421
.:@0.909810:0.297893:0.914548:0.297893:0.914548:0.283887:0.909810:0.283887:0.004738
Superior  vane cava obstruction.  Is it a:@0.559983:0.312392:0.914556:0.312392:0.914556:0.298387:0.559983:0.298387:0.008518:0.010399:0.011665:0.011118:0.005148:0.003421:0.011203:0.005148:0.004738:0.007324:0.009476:0.011682:0.010434:0.011118:0.012076:0.011067:0.011682:0.009476:0.011682:0.012076:0.011203:0.011665:0.006636:0.005798:0.005148:0.010399:0.011067:0.005798:0.003421:0.011203:0.010422:0.004738:0.004738:0.007329:0.003866:0.006636:0.012076:0.003421:0.005798:0.012076:0.011682
medical emergency? :@0.559983:0.326891:0.745182:0.326891:0.745182:0.312886:0.559983:0.312886:0.016044:0.011118:0.011716:0.003421:0.011067:0.011682:0.003421:0.005148:0.011118:0.016044:0.011118:0.005159:0.011511:0.011118:0.010434:0.011067:0.009168:0.010109:0.004738
American Journal of:@0.745593:0.326891:0.914558:0.326891:0.914558:0.312886:0.745593:0.312886:0.012657:0.016044:0.011118:0.005148:0.003421:0.011067:0.011682:0.010434:0.005140:0.008244:0.011203:0.010399:0.005148:0.010434:0.011682:0.003421:0.005148:0.011203:0.005371
Medicine:@0.559983:0.341390:0.637996:0.341390:0.637996:0.327385:0.559983:0.327385:0.015719:0.011118:0.011716:0.003421:0.011067:0.003421:0.010434:0.011118
. 1981;70(6):1169.:@0.637996:0.341390:0.778543:0.341390:0.778543:0.327385:0.637996:0.327385:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
17.   National Comprehensive Cancer Network:@0.523636:0.355889:0.914558:0.355889:0.914558:0.341884:0.523636:0.341884:0.009476:0.009476:0.004738:0.012657:0.004738:-0.004738:0.012657:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.006842:0.013906:0.011203:0.016044:0.011665:0.005077:0.011118:0.010434:0.011118:0.010434:0.006636:0.003421:0.009476:0.011118:0.006859:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.006847:0.012657:0.011118:0.005798:0.014214:0.011203:0.005148:0.051287
(NCCN). NCCN Clinical practice guidelines :@0.559983:0.370389:0.919291:0.370389:0.919291:0.356383:0.559983:0.356383:0.006312:0.012657:0.013906:0.013906:0.012657:0.006312:0.004738:0.004002:0.012657:0.013906:0.013906:0.012657:0.004002:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.004016:0.011665:0.005148:0.011682:0.011067:0.005798:0.003421:0.011067:0.011118:0.004002:0.011511:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.006636:0.004738
in oncology. Cancer-associated venous:@0.559983:0.384888:0.914546:0.384888:0.914546:0.370882:0.559983:0.370882:0.003421:0.010434:0.012503:0.011203:0.010434:0.011067:0.011193:0.003421:0.011203:0.011511:0.009168:0.004738:0.012503:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.005679:0.011682:0.006636:0.006636:0.011203:0.011067:0.003421:0.011682:0.005798:0.011118:0.011716:0.012503:0.009476:0.011118:0.010434:0.011203:0.010399:0.006636
thromboembolic disease. Version 1. 2017.:@0.559983:0.399387:0.914551:0.399387:0.914551:0.385382:0.559983:0.385382:0.005798:0.010434:0.005073:0.011203:0.016044:0.011665:0.011203:0.011118:0.016044:0.011665:0.011203:0.003421:0.003421:0.011067:0.008261:0.011716:0.003421:0.006636:0.011118:0.011682:0.006636:0.011118:0.004738:0.008261:0.010281:0.011118:0.005148:0.006636:0.003421:0.011203:0.010434:0.008261:0.009476:0.004738:0.008261:0.009476:0.009476:0.009476:0.009476:0.004738
http://www.nccn.org/professionals/physi-:@0.559983:0.413886:0.902804:0.413886:0.902804:0.399881:0.559983:0.399881:0.010434:0.005798:0.005798:0.011665:0.004738:0.007475:0.007475:0.014214:0.014214:0.014214:0.004738:0.010434:0.011067:0.011067:0.010434:0.004738:0.011203:0.005148:0.011511:0.007475:0.011665:0.005078:0.011203:0.005371:0.011118:0.006636:0.006636:0.003421:0.011203:0.010434:0.011682:0.003421:0.006636:0.007475:0.011665:0.010434:0.009168:0.006636:0.003421:0.005679
cian_gls/f_guidelines.asp. Accessed Janu-:@0.559983:0.428385:0.914556:0.428385:0.914556:0.414380:0.559983:0.414380:0.011067:0.003421:0.011682:0.010434:0.008552:0.011511:0.003421:0.006636:0.007475:0.005371:0.008552:0.011511:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.006636:0.004738:0.011682:0.006636:0.011682:0.004738:0.007663:0.012657:0.011067:0.011067:0.011118:0.006636:0.006636:0.011118:0.011716:0.007663:0.008244:0.011682:0.010434:0.010399:0.005679
ary 2018).:@0.559983:0.442884:0.639672:0.442884:0.639672:0.428879:0.559983:0.428879:0.011682:0.005148:0.009168:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
18.    Kvale PA, Selecky PA, Prakash UB, :@0.523636:0.457384:0.821639:0.457384:0.821639:0.443378:0.523636:0.443378:0.009479:0.009479:0.004731:0.004738:0.007919:0.004738:-0.004738:0.009596:0.008963:0.011169:0.002908:0.010605:0.003985:0.008347:0.012144:0.004225:0.003985:0.008005:0.010605:0.002908:0.010605:0.010553:0.008073:0.008655:0.003985:0.008340:0.012144:0.004225:0.003985:0.009613:0.004635:0.011169:0.008073:0.011169:0.006123:0.009921:0.003985:0.010690:0.009305:0.004225:-0.007270
et al:@0.820886:0.457384:0.855351:0.457384:0.855351:0.443378:0.820886:0.443378:0.010605:0.005285:0.003985:0.011169:0.003421
. Ameri-:@0.854838:0.457384:0.914550:0.457384:0.914550:0.443378:0.854838:0.443378:0.004225:0.003985:0.012144:0.015531:0.010605:0.004635:0.002908:0.005679
can College of Chest Physicians (ACCP). Pal-:@0.559983:0.471883:0.914556:0.471883:0.914556:0.457877:0.559983:0.457877:0.010553:0.011169:0.009921:0.004721:0.013393:0.010690:0.002908:0.002908:0.010605:0.010998:0.010605:0.004721:0.010690:0.004858:0.004721:0.013393:0.009921:0.010605:0.006123:0.005285:0.004721:0.009613:0.009921:0.008655:0.006123:0.002908:0.010553:0.002908:0.011169:0.009921:0.006123:0.004721:0.005798:0.012144:0.013393:0.013393:0.009613:0.005798:0.004225:0.004721:0.009613:0.011169:0.002908:0.005679
liative care in lung cancer: ACCP evidence-:@0.559983:0.486382:0.914562:0.486382:0.914562:0.472377:0.559983:0.472377:0.002908:0.002908:0.011169:0.005285:0.002908:0.008963:0.010605:0.005867:0.010553:0.011169:0.004565:0.010605:0.005858:0.002908:0.009921:0.005858:0.002908:0.009886:0.009921:0.010998:0.005857:0.010553:0.011169:0.009921:0.010553:0.010605:0.004635:0.004225:0.005858:0.012144:0.013393:0.013393:0.009613:0.005858:0.010605:0.008963:0.002908:0.011203:0.010605:0.009921:0.010553:0.010605:0.005679
based clinical practice guidelines (2nd ed).:@0.559983:0.500881:0.914505:0.500881:0.914505:0.486876:0.559983:0.486876:0.011152:0.011169:0.006123:0.010605:0.011203:0.007458:0.010553:0.002908:0.002908:0.009921:0.002908:0.010553:0.011169:0.002908:0.007458:0.011152:0.004635:0.011169:0.010553:0.005285:0.002908:0.010553:0.010605:0.007458:0.010998:0.009886:0.002908:0.011203:0.010605:0.002908:0.002908:0.009921:0.010605:0.006123:0.007458:0.005798:0.008963:0.009921:0.011203:0.007458:0.010605:0.011203:0.005798:0.004738
Chest. :@0.559983:0.515380:0.614272:0.515380:0.614272:0.501375:0.559983:0.501375:0.013393:0.009921:0.010605:0.006123:0.005285:0.004225:0.004738
2007 Sep;132(Suppl3):368S-403S.:@0.613759:0.515380:0.862286:0.515380:0.862286:0.501375:0.613759:0.501375:0.008963:0.008963:0.008963:0.008963:0.004225:0.008005:0.010605:0.011152:0.004225:0.008963:0.008963:0.008963:0.005798:0.008005:0.009886:0.011152:0.011152:0.002908:0.008963:0.005798:0.004225:0.008963:0.008963:0.008963:0.008005:0.005166:0.008963:0.008963:0.008963:0.008005:0.004738
19.   UpToDate  ©  Consensus-based  Guidelines.:@0.523636:0.529879:0.914536:0.529879:0.914536:0.515874:0.523636:0.515874:0.009476:0.009476:0.004738:0.012657:0.004738:-0.004738:0.011203:0.011665:0.006448:0.011203:0.012726:0.011682:0.005798:0.011118:0.004738:0.002824:0.012777:0.004738:0.002827:0.013906:0.011203:0.010434:0.006636:0.011118:0.010434:0.006636:0.010399:0.006636:0.005679:0.011665:0.011682:0.006636:0.011118:0.011716:0.004738:0.002829:0.014915:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.006636:-0.205616
Malignancy-related superior vena cava:@0.559983:0.544379:0.914541:0.544379:0.914541:0.530373:0.559983:0.530373:0.015719:0.011682:0.003421:0.003421:0.011511:0.010434:0.011682:0.010434:0.011067:0.009168:0.005679:0.005082:0.011118:0.003421:0.011682:0.005798:0.011118:0.011716:0.013016:0.006636:0.010399:0.011665:0.011118:0.005148:0.003421:0.011203:0.005148:0.013016:0.009476:0.011118:0.010434:0.011682:0.013016:0.011067:0.011682:0.009476:0.011682
syndrome.  https://www.uptodate.com/:@0.559983:0.558878:0.914558:0.558878:0.914558:0.544872:0.559983:0.544872:0.007321:0.009852:0.011118:0.012401:0.005761:0.011888:0.016728:0.011802:0.005422:0.004738:0.003819:0.011118:0.006483:0.006483:0.012349:0.007321:0.005422:0.008159:0.008159:0.014898:0.014898:0.014898:0.005422:0.011084:0.012349:0.006483:0.011888:0.012401:0.012366:0.006483:0.011802:0.005422:0.011751:0.011888:0.016728:0.007475
contents/malignancy-related-superior-ve-:@0.559983:0.573377:0.902171:0.573377:0.902171:0.559372:0.559983:0.559372:0.010553:0.010690:0.009921:0.005285:0.010605:0.009921:0.005285:0.006123:0.006961:0.016044:0.011682:0.003421:0.003421:0.011511:0.010434:0.011682:0.010434:0.011067:0.009168:0.005679:0.005078:0.011118:0.003421:0.011682:0.005798:0.011118:0.011716:0.005679:0.006636:0.010399:0.011665:0.011118:0.005148:0.003421:0.011203:0.005148:0.005679:0.009476:0.011118:0.005679
na-cava-syndrome?search=superior%20:@0.559983:0.587876:0.909593:0.587876:0.909593:0.573871:0.559983:0.573871:0.010947:0.012195:0.006192:0.011580:0.012195:0.009989:0.012195:0.006192:0.007150:0.009681:0.010947:0.012230:0.005590:0.011716:0.016557:0.011631:0.010622:0.007150:0.011631:0.012195:0.005542:0.011580:0.010947:0.010878:0.007150:0.010913:0.012178:0.011631:0.005662:0.003934:0.011716:0.005662:0.013769:0.009989:0.009476
vena%20cava%20syndrome&source=:@0.559983:0.602375:0.910858:0.602375:0.910858:0.588370:0.559983:0.588370:0.010844:0.012486:0.011802:0.013051:0.014624:0.010844:0.010844:0.012435:0.013051:0.010844:0.013051:0.014624:0.010844:0.010844:0.008005:0.010536:0.011802:0.013085:0.006445:0.012572:0.017412:0.012486:0.014316:0.008005:0.012572:0.011768:0.006397:0.012435:0.012486:0.010365
search_result&selectedTitle=1~150&usag:@0.559983:0.616874:0.895268:0.616874:0.895268:0.602869:0.559983:0.602869:0.006636:0.011118:0.011682:0.005030:0.011067:0.010434:0.008552:0.005077:0.011118:0.006636:0.010399:0.003421:0.005798:0.012948:0.006636:0.011118:0.003421:0.011118:0.011067:0.005798:0.011118:0.011716:0.007806:0.003421:0.005798:0.003421:0.011118:0.010365:0.009476:0.010365:0.009476:0.009476:0.009476:0.012948:0.010399:0.006636:0.011682:0.011511
e_type=default&display_rank=1#H18.  Ac-:@0.559983:0.631374:0.914544:0.631374:0.914544:0.617368:0.559983:0.617368:0.011118:0.008552:0.005798:0.009168:0.011665:0.011118:0.010365:0.011716:0.011118:0.005371:0.011682:0.010399:0.003421:0.005798:0.012948:0.011716:0.003421:0.006636:0.011665:0.003421:0.011682:0.009168:0.008552:0.005148:0.011682:0.010434:0.008586:0.010365:0.009476:0.012315:0.011682:0.009476:0.009493:0.004738:0.004738:0.010524:0.012657:0.011067:0.005679
cessed January 2018.:@0.559983:0.645873:0.737150:0.645873:0.737150:0.631867:0.559983:0.631867:0.011067:0.011118:0.006636:0.006636:0.011118:0.011716:0.004738:0.008244:0.011682:0.010434:0.010399:0.011682:0.005148:0.009168:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738